39856-56-9

Usage

Uses

Used in Chemical Catalysts:
6-Bromo-N,N-dimethylpyridine-3-amine is used as a catalyst in various chemical reactions, such as acylation and alkylation processes. Its high reactivity and ability to facilitate reactions under mild conditions make it a valuable component in these processes.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 6-Bromo-N,N-dimethylpyridine-3-amine is used for the synthesis of various compounds. Its unique properties and reactivity contribute to the development of new pharmaceutical products.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, 6-Bromo-N,N-dimethylpyridine-3-amine is utilized for the synthesis of compounds used in agricultural applications. Its role in creating new agrochemicals helps improve crop protection and productivity.
However, it is important to handle 6-Bromo-N,N-dimethylpyridine-3-amine with caution, as it can be toxic and harmful if not used properly. Proper safety measures and guidelines should be followed to ensure the safe use of 6-BroMo-n,n-diMethylpyridine-3-aMine in various applications.

Upstream product

• 13534-97-9 6-bromopyridine-3-amine 
• 50-00-0 formaldehyd 
• 74-88-4 methyl iodide 
• 18437-57-5 3-dimethylaminopyridine 

Downstream Products

• 934477-86-8 2-(2,4-difluorophenyl)-5-dimethylamino-pyridine 
• 37941-28-9 N,N-dimethyl-6-phenylpyridin-3-amine 
• 856014-55-6 6-amino-4-(3-bromophenyl)-5'-dimethylamino-[2,2']bipyridyl-5-carbonitrile 
• 214701-20-9 1-(5-(dimethylamino)pyridin-2-yl)ethanone 

Relevant academic research and scientific papers

Aryl-Diadamantyl Phosphine Ligands in Palladium-Catalyzed Cross-Coupling Reactions: Synthesis, Structural Analysis, and Application

Synthesis, temperature-dependent NMR structure investigation and utilization of a new, stable and easily accessible aryl-diadamantylphosphine ligand family is reported. The bulky and electron-rich phosphorus center of the ligand enhances the catalytic activity of palladium in cross-coupling reactions of sterically demanding ortho-substituted aryl halides. In our study, we demonstrated the synthetic applicability of the new phosphine ligands in Buchwald-Hartwig and tosyl hydrazone coupling reactions.

CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase L1 (UCHL1) and ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of cancer and conditions involving mitochondrial dysfunction. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1,R2,R3,R4,R5,R6,R7,R8 and R9 are as defined herein.

The Role of Substituent Effects in Tuning Metallophilic Interactions and Emission Energy of Bis-4-(2-pyridyl)-1,2,3-triazolatoplatinum(II) Complexes

The photoluminescence spectra of a series of 5-substituted pyridyl-1,2,3-triazolato PtII homoleptic complexes show weak emission tunability (ranging from λ=397-408 nm) in dilute (10-6 M) ethanolic solutions at the monomer level and strong tunability in concentrated solutions (10-4 M) and thin films (ranging from λ=487-625 nm) from dimeric excited states (excimers). The results of density functional calculations (PBE0) attribute this "turn-on" sensitivity and intensity in the excimer to strong Pt-Pt metallophilic interactions and a change in the excited-state character from singlet metal-to-ligand charge transfer (1MLCT) to singlet metal-metal-to-ligand charge transfer (1MMLCT) emissions in agreement with lifetime measurements. Turn-on tunability: A series of bis-4-(2-pyridyl)-1,2,3-triazolatoplatinum(II) complexes display variable emission tunability. At low concentration, the emission can be tuned only slightly by changing the nature of the substituent but at higher concentrations tunability is enhanced. This "turn-on" sensitivity in the excimeric emission is attributed to strong Pt-Pt metallophilic interactions and a change in the excited-state character.

PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES

Pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts are disclosed, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha- synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, the compounds are used as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. Futher, the compounds are useful for measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.

Light-Emitting Material

This invention pertains to light emitting materials comprising novel ortho-metalated transition metal complexes [C?N]2ML, comprising chelate monoionic ligands (L), also called ancillary ligands. It has been surprisingly found that when the ancillary ligand comprises a substituted aromatic ring bearing a substituent possessing adequate electron-donating properties, said ligand (L) advantageously participates in the emission process, significantly shifting emission towards higher energies (blue-shift) and enabling appreciable improvement of the emission efficiency of complexes [C?N]2ML. Still objects of the invention are the use of said light emitting materials and organic light emitting device comprising said light emitting material.

5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d] pyrimidin-4-ylamine: Structure-activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors

4-Amino-5,7-disubstituted pyridopyrimidines are potent, non-nucleoside inhibitors of adenosine kinase (AK). We recently identified a potent, orally efficacious analog, 4 containing a 7-pyridylmorpholine substituted ring system as the key structural element of this template. In this report, we disclose the pharmacologic effects of five- and six-membered heterocyclic ring replacements for the pyridine ring in 4. These replacements were found to have interesting effects on in vivo efficacy and genotoxicity as well as in vitro potency. We discovered that the nitrogen in the heterocyclic ring at C(7) is important for the modulation of mutagenic side effects (Ames assay).

Syntheses of 5,5-disubstituted 2,2'-bipyridines

New and improved syntheses of 5,5'-donor-functionalized 2,2'-bipyridines are reported with the 5,5'-donors being -NH2 (4), -NMe2 (5), -CN (6), and - NCS (7). A new route for 4 and 5 is based on the coupling of 2-chloro-5- amino-pyridine in the presence of NiCl2 · 6 H2O/PPh3/Zn in DMF (NiCRA) · 6 was obtained by a dehydration treatment of 5,5'-dicarboxamide-2,2'- bipyridine with (F3CCO)2O and P4O10. The new ligand 7 is prepared from 4 and SCCl2.